Revolutionize binding for the future of cell & antibody therapeutics
There are no simple answers to immuno-oncology’s greatest challenges
Many immunotherapies adapt to solve the field’s most pressing issues (an intricate balance between persistence, potency, and safety) by integrating multiple signaling mechanisms and engaging with more than one target in parallel. With that trend, the binding mechanisms between binder and target also complexify.
Yet, most binding assays haven’t kept up.
- Molecular assays like tetramer binding and surface plasmon resonance (SPR) offer simplified snapshots. Focusing on isolated ligand-receptor interactions or abundance on a molecular level, they can miss the cellular context and often do not correlate well with functional outcomes.
- Functional assays such as cytotoxicity and activation assays generally measure the outcome of binding yet may fail to provide direct mechanistic insights inhibiting rationally driven design choices. This creates a gap between what we can measure and what we need to understand to advance next-generation immunotherapies.
Many immunotherapies adapt to solve the field’s most pressing issues (an intricate balance between persistence, potency, and safety) by integrating multiple signaling mechanisms and engaging with more than one target in parallel. With that trend, the binding mechanisms between binder and target also complexify.
Cell Avidity, the missing link
Cell Avidity bridges that gap. By measuring the combined strength of cell-cell / cell-protein binding with controlled forces, Cell Avidity generates direct, physiologically relevant measurements of binding in its full, dynamic complexity. Applied to cell or antibody binding research, in experiments on functional modifications or microenvironment modulators, Cell Avidity is shown to reveal the mechanisms of action, facilitating rational design choices, selecting the right candidates fast and early, and ultimately improving therapeutic outcomes.
To support progress in immunotherapy, we need to measure binding the way it happens—in real life, in real cells.
This is Cell Avidity.
Go beyond affinity. Select leads based on their binding in a cellular context.
Understand the MoA of your therapeutic products by revealing its complex binding dynamics
Balance potency & safety by optimizing binding
Unlock faster R&D cycles through more rational drug design
Workflow
The Cell Avidity workflow
Cell Avidity: Assays that measure the overall strength of interaction between cells, or between proteins and cells.
Target cell seeding
Target cells (adherent or non-adherent) are generally of two types:
- Tumor cells to assess potency or antigen sensitivity
- Healthy cells to assess on-target off-tumor toxicity
Effector cell / molecule introduction
Introduction of labeled binders to the uniform monolayer. These can include:
- Therapeutic effector cell products like CAR T, TCR T, NK.
- Effector cells with compound drugs such as cell engagers, small molecule inhibitors or modified environmental factors.
- Fluorescent beads coated with antibodies or other proteins.
Controlled force application & fluorescent imaging
Controlled force applied to the bound cells probes the strength of interactions between labeled and target populations.
Fluorescence microscopy captures the number of bound cells before and after force application. The percentage of bound cells after force application indicates the population’s Cell Avidity.
Instant data acquisition
Cell Avidity quantifies cell binding with hundreds of cells per measurement.
- Percentage (%) of cells bound
- Percentage (%) of antibody-coated beads bound.
Applications
Explore your research application
Explore what Cell Avidity can mean for your field of interest
Cell Engagers
Accelerate your cell engager discovery
Determine avidity EC50 and binding kinetics of T cell engagers to quantify trimer formation across multiple dimensions in the cell-cell context.
Available case studies:
Balancing pharmacokinetic benefits with cell avidity optimization for cell engager success
Case study
Antibody Therapy
Quickly rank large pools of antibody candidates
Elucidate binding effects of antibodies within the 2D membrane-constrained cellular environment, taking into account the effects of epitope, steric hindrance, and multivalency.
Available case studies:
Cell Avidity measures true binding of biparatopic antibodies
Case study
Cell Therapy
Complete cell-cell binding characterization
Steer receptor binding to overcome cell therapy exhaustion, improve potency, minimize OTOT, and refine binding sensitivity to overcome immune escape.
Available case studies:
Cell Avidity tackles on-target off-tumor toxicity in novel CAR-T therapy
Case study
When Cell Avidity insights would have prevented clinical trial failure: the APRIL-CAR retrospective
Case study
Industry
Unlock faster R&D cycles
Integrating Cell Avidity in the drug development workflow leads to faster identification of the most potent, safe and sensitive drug candidate by reducing the required number of design iterations or eliminating candidates from in vivo preclinical studies which ultimately bind ineffectively in a cellular context.
Early in the pipeline - Select the right candidates fast
Quickly rank hundreds to thousands of therapeutic candidates to get insights into sensitivity and safety. Incorporate Cell Avidity early in the discovery workflow helps ensure that only candidates with the most promising binding characteristics progress.
Late-stage - Deep candidate characterization to drive clinical selection
Carry out deep functional characterization of select final candidates. Reveal differences in binding dynamics and target engagement to confidently select the optimal therapeutics for clinical development.
Solutions
Avidion
The next generation Cell Avidity platform
Ideal for cell therapy candidate screening and large characterization studies. Run up to 4 disposable 48-well cartridges a day for a total of 192 measurements with <80 min. hands-on time.
Avidigo
White glove Cell Avidity services
Full-service contract research from experimental design to data report based on Cell Avidity measurements at high throughput.
z-Movi
For small sized Cell Avidity studies
A fast and simple solution for single-sample Cell Avidity experiments. Run up to 20 measurements per day.
Key content
Discover all the details
Cell Avidity Technology Brochure
Brochure
The latest all-in-one overview of our Cell Avidity technology.
Technical note:
Filter CA shows 3 items
There is a hidden collection to add multiple authors to this publication.
This section is hidden when emtpy.
To keep everything visible here, that is being done outside the webflow designer from within Slater.
Filter CA shows 3 items
There is a hidden collection to add multiple authors to this publication.
This section is hidden when emtpy.
To keep everything visible here, that is being done outside the webflow designer from within Slater.
Text Link
Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma
Chaturantabut, S. et al.
2025
J. Clin. Investigation
https://www.jci.org/articles/view/182417
Publication
Text Link
Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR T Cells for Myeloid Leukemia
Leick, M. B. et al.
2022
Cancer Cell
https://doi.org/10.1016/j.ccell.2022.04.001
Publication
Technical note:
Filter CA and show 4 Latest
This shows the most recent card of each resource type filtered on Business Unit CA.
Webinar, Scientific update, Whitepaper, Application note, Brochure.
We only show 4 and we have 6 types so the 2 older ones are hidden.
In design only 1 is shown, but the rest will be loaded when published.
Filter CA and show 4 Latest
This shows the most recent card of each resource type filtered on Business Unit CA.
Webinar, Scientific update, Whitepaper, Application note, Brochure.
We only show 4 and we have 6 types so the 2 older ones are hidden.
In design only 1 is shown, but the rest will be loaded when published.
Button Text
Identification of potent biparatopic antibodies targeting FGF receptors in solid tumours
Webinar
May 23, 2025
01-01-20
Translocations involving FGFR2 gene fusions are common in cholangiocarcinoma and gastric carcinoma and predict response to FGFR kinase inhibitors. However, response rates and durability are limited due to the emergence of resistance, typically involving FGFR2 kinase domain mutations, and to sub-optimal dosing, relating to adverse drug effects.
This webcast will present new work showing that the vast majority of such alterations retain the extracellular domain (ECD), potentially enabling highly selective targeting of the FGFR2 ECD using biotherapeutics.
To improve on the activity of traditional bivalent monotopic antibodies, the Sellers lab systematically generated biparatopic antibodies targeting distinct epitope pairs in FGFR2 ECD, and identified antibodies that effectively block signaling and malignant growth driven by FGFR2-fusions.
These antibodies robustly blocked proliferation and colony formation in FGFR2-fusion driven cholangiocarcinoma and demonstrated robust in vivo anti-tumour activity. In vivo activity was marked by significant antibody-mediated downregulation of FGFR2 and in turn this was associated with robust lysosomal internalization enacted by the two biparatopics. In vitro, the biparatopic antibodies demonstrated activity against FGFR inhibitor resistant alleles of FGFR2. The internalization properties of the antibodies also make them suitable for exploration as antibody-drug conjugates
Text Link
Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers
Scientific update
January 29, 2025
01-01-20
Cell Avidity: a key to accelerate IND filing in cell therapy drug development
Whitepaper
July 1, 2023
01-01-20
Cell Avidity measures true binding of biparatopic antibodies
Application note
April 23, 2025
01-01-20
Mechanistic issues limit the effectiveness of many current cancer-targeting antibody therapies, with monospecific antibodies often hindered by receptor dimerization and activation. Biparatopic antibodies, which bind to two unique non-overlapping epitopes, offer a promising solution with stronger binding, more potent antagonism, and higher specificity.
Avidigo Service Brochure
Brochure
May 1, 2025
01-01-20
SITC 2025
Conference
April 22, 2025
01-01-20
CAR-TCR Summit 2025
Conference
April 22, 2025
01-01-20
CICON 2025
Conference
April 22, 2025
01-01-20
Let’s get in touch
Our team is standing by to help you
See more. Know more.
We empower the academic and pharmaceutical communities with cutting-edge technologies to deeply understand the mechanisms of life and disease, driving the discovery and development of life-saving therapies
All products and technologies are for Research Use Only (RUO) except when specifically noted